skip to Main Content

Thank you for exploring Full Spectrum Synergy with OM Extracts! We offer playshops, learning experiences, and literature which are all grounded by the research findings of peer-reviewed scientific references. Email to learn about free training for Oregon dispensaries and free resources for Cannabis professionals around the world! Explore Infographics, Cannabis Interviews, Education, and Scientific Resources below:

Click to Download 2-sided OM Extracts Full Spectrum Synergy Printable PDF

OM Extracts Full Spectrum Synergy 1 Cannabis Flower Biology

OM Extracts Full Spectrum Synergy 2 Cannabis Flowers Consituents and Ensemble Effect

OM Extracts Full Spectrum Synergy 3 - Endocannabinoid System and Primary Cannabis Extracts

OM Extracts Full Spectrum Synergy 4 Refined Cannabis Extracts and How to Find Clean Cannabis

OM Extracts Full Spectrum Synergy 5 Raw CO2 FECO Winterized and Cannaceutical Tincture

OM Extracts Full Spectrum Synergy 6 Mission Vision Contact

2021 OM Extracts Interview with


  • Learn how OM Extracts makes Full Spectrum Cannabis and Hemp Extracts using CO2 (Carbon Dioxide)
  • Read about which Cannabis extracts may be right for you
  • Explore recommendations for people who have never tried Canna oils before
  • Review top 3 trends for 2021 Cannabis
  • Consider our predictions for the next five years of Cannabis and Hemp 

2019 OM Extracts Interview with Periodic Effects Cannabis Business & Science Podcast

  • Learn about the importance of pure Cannabis extracts with no additives, especially for vaping
  • Consider the dangers of common vape additives, like Vitamin E acetate 
  • Listen to a step-by-step explanation of how Cannabis flower becomes Cannabis extracts
  • 2021 Update: Since recording this episode, Oregon Cannabis Vape products must now label if they have any non-Cannabis derived ingredients. Oregonians advocated for increased Cannabis vape safety measures, lawmakers changed the rules, and now the customers are safer and more informed with updated labels. Learn about the science and take a stand: the regulatory bodies are listening to your feedback and rule change suggestions!

What is CBG?

Cannabigerol (CBG) is a common cannabinoid that has been getting more scientific attention recently. The Cannabis plant can contain upwards of 100+ Cannabinoids, and CBG is the precursor to all Cannabinoids in immature Cannabis plants. Despite how common it is in low potencies in immature plants, CBG is still quite rare in finished Cannabis flowers at large therapeutic doses. Oregon CBD has bred a variety called “CBG White” which we have available now. Read on for more about CBG, or skip straight to our Canna-Lite page for more about our CBG White!

Check out some of the latest CBG Research:

  • Stress and Anxiety: CBG may affect serotonin and adrenaline uptake, affecting stress/anxiety and typically boosting mood. In this article, the authors reference CBG as “highly potent against for α2 adrenoceptor and a blocker of serotonin 5-HT1A receptor [which] underscores the potential importance of [CBG] and other alkaloids in the psychoactive profile of cannabis.”
  • Pain Relief: “Based on its antioxidant activities, CBG may hold great promise as an anti-oxidant agent and therefore used in clinical practice as a new approach in oxidative-stress related disorders.”
  • Neuroprotection, Neuromodulators, and Antioxidant Effects: “…these results indicated the neuroprotective effects of CBG, that may be a potential treatment against neuroinflammation and oxidative stress.” and“Neuroprotective and Neuromodulatory Effects Induced by Cannabidiol and Cannabigerol in Rat Hypo-E22 cells and Isolated Hypothalamusis a fascinating read, with this take-home message: “The CBD modulates hypothalamic neuromodulators consistently with its anorexigenic role, whereas the CBG effect on the same mediators suggests alternative mechanisms, possibly involving peripheral pathways.” In other words, CBD and CBG may both have big positive effects on the part of the brain responsible for regulating temperature, hunger, sleep, and hormones: the thalamus. Neuroprotectors and neuromodulators repair, rebuild, and regenerate the nervous system, its cells, structures, and functions. 
  • Autoimmune Disorders: “This study highlights the therapeutic potential of VCE-003 [A cannabigerol quinone] as an agent for the treatment of human immune diseases with both inflammatory and autoimmune components.”
  • Multiple Sclerosis (MS): “A cannabigerol quinone, the compound VCE-003, has been shown to alleviate symptoms in a viral model of multiple sclerosis (MS).”
  • Cancer: “Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid”
  • Inflammatory Bowel Disease: “The CB2 receptor pathway was also found to modulate the favorable effects of cannabigerol (CBG), a non-psychotropic cannabinoid capable of reducing nitric oxide production in macrophages and attenuating murine DNBS-induced colitis in both a preventive (pretreatment) model and therapeutic (established colitis) model”
  • MRSA: Uncovering the hidden antibiotic potential of Cannabis is an in-depth journal article about CBG and MRSA, and notes that Cannabinoids are much safer than most commercially-available antibacterial agents due to the antibiotic resistance of many common bacteria.
  • Dental Health: CBG along with other cannabinoids “were more effective in reducing the bacterial colony count in dental plaques as compared to the well-established synthetic oral care products such as Oral B and Colgate.”  The Pub Med article Comparison of Efficacy of Cannabinoids versus Commercial Oral Care Products in Reducing Bacterial Content from Dental Plaque concludes “cannabinoids have the potential to be used as an effective antibacterial agent against dental plaque-associated bacteria. Moreover, it provides a safer alternative for synthetic antibiotics to reduce the development of drug resistance.”

How are CBG and CBD Similar and Different?

  • Both offer non-intoxicating effects
  • Both are researched for anxiety, pain, inflammation, sleep, and more
  • CBD only interacts with the CB2 receptor, while CBG interacts with both the CB1 and CB2 receptors. This means CBG may affect the nervous system more than CBD Source Cited
  • “​​Studies indicate that CBG may have therapeutic potential in treating neurological disorders (e.g., Huntington’s disease, Parkinson’s disease, and Multiple Sclerosis) and inflammatory bowel disease, as well as having antibacterial activity…”
  • “First, there is potential for CBG as a major player in the treatment of metabolic disease…to improve insulin sensitivity and adipogenesis…”
  • “Second, several studies have described the neuroprotective effects of CBG…Other sources have reported a reduction in age-related cognitive decline in patients with neurodegenerative disease…”
  • “Third, similar to other phytocannabinoid derivatives, CBG may play an important role for improving the drug cocktails of patients who struggle with disorders of executive function, such as schizophrenia and ADHD”
  • “Finally, researchers have studied the effects of CBG as a safe appetite stimulant in chemotherapy-related appetite suppression in vitro and as an agent that reduces in vitro signs of pathology in colitis and colorectal cancer.” Source Cited
  • CBG affects how the body uptakes adrenaline (specifically, noradrenaline) which may affect anxiety, sleep, and muscle tissue Source Cited
  • CBG may offer more muscle relief compared to CBD Source Cited

What is CBC?

Cannabichromene is an often overlooked Cannabinoid that has been under the research spotlight recently and is found naturally occurring in many OM Extracts products. This research roundup and quotes are from Leafly.

CBC works together with other Cannabinoids (see “the Ensemble Effect” above), and it is non-intoxicating. Although CBC doesn’t bind to CB1 cannabinoid receptors in the brain, it does bind with many other receptors that are linked to pain perception including the vanilloid receptor 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1). The body releases more of its natural endocannabinoids, including anandamide, when CBC activates the TRPV1 and TRPA1. Source Cited

  • Cancer: “CBC as a potential cancer fighter was first published in a 2006 study that looked at cannabinoids other than THC and their possible effects on cancer. While THC is known for its anti-tumor properties for several different forms of cancer, its powerful psychotropic qualities can make it difficult for chemotherapy use. So far, research has found CBC to be the second-most-potent cannabinoid at inhibiting the growth of new cancer cells (CBG was the most potent).” Source Cited  
  • Pain and Inflammation: “Cannabichromene has been shown to block pain and inflammation associated with collagen-induced osteoarthritis. Cannabinoids like CBC act on inflammation differently than non-steroidal anti-inflammatory drugs (NSAIDs) do, and don’t have the side effects of these medications. In another example of the entourage effect, CBC in combination with THC had significant anti-inflammatory response in a recent animal study; together, the two cannabinoids produced a much greater effect on inflammation than by themselves.” Source 1 Source 2 Source 3
  • Brain Cells: “In a 2013 mouse study, CBC had a positive effect on neural stem progenitor cells (NSPCs), a cell essential to healthy brain function. NSPCs became more viable when in the presence of CBC, and that shows promise because NSPCs differentiate into astroglial cells, the most important cells for maintaining brain homeostasis. The astroglial cells perform a whole host of functions, including neurotransmitter direction and defending against oxidative stress. Astroglia counteracts many of these issues—oxidative stress, inflammation, toxicity—that create neurological diseases and brain pathologies like Alzheimer’s disease.” Source 1 Source 2
  • Acne: “A research team that had previously shown CBD’s effect on acne studied other cannabinoids, including CBC, for the same effects. Indeed, CBC was shown to be a powerful inhibitor of acne. As a skin disease, acne is characterized by excess sebum production and sebaceous gland inflammation. It turns out that CBC exhibited powerful anti-inflammatory properties and also suppressed excessive lipid production in the sebaceous glands. CBC also reduced levels of arachidonic acid (AA), which is needed to create lipogenesis. More research is needed, but CBC might just one day become a very powerful anti-acne treatment. Source Cited
  • Depression: “In another amazing display of the entourage effect, CBC appears to work in conjunction with both THC and CBD to deliver a trifecta of antidepressant properties.” Source Cited

What are the “raw” Acid-state Cannabinoids?

These medicinal acid molecules include THCa, CBDa, CBCa, CBGa, and more. While there isn’t enough research to definitively review their medicinal uses and values, preliminary research and anecdotal evidence suggest they will play a pivotal role in Cannabis medicine as the industry propels forward. In many studies, researchers found Cannabinoids were more effective for certain treatments when consumed raw. Here are some areas of research and possible benefits: 

  • Nausea and Vomiting: “THCa may be a more potent alternative to THC in the treatment of nausea and vomiting.” “THCa may be a more desirable therapeutic treatment for nausea and vomiting than THC because it is both more potent and devoid of psychoactive properties. There is an intriguing parallel between the effects of THCa and the acid precursor of CBD, CBDa, on nausea and vomiting in our models.” Source Cited
  • Neurodegenerative Diseases: “THCa and CBD treatment at a concentration of 10 μM lead to significantly increased cell counts [of tyrosine hydroxylase immunoreactive neurons] to 123% and 117%, respectively. Even though no significant preservation or recovery of neurite outgrowth to control values could be observed, our data show that cannabinoids THC and THCa protect dopaminergic neurons against MPP(+) induced cell death.” Source Cited
  • Breast Cancer: “the results obtained here demonstrated that i) CBDA had dual inhibitory effects on COX-2 through down-regulation and enzyme inhibition, and ii) CBDa may possess the ability to suppress genes that are positively involved in the metastasis of cancer cells in vitro.” Source Cited
  • Diabetes and Diabetic Complications: “Aldose reductase (ALR2) is a key enzyme involved in diabetic complications and the search for new aldose reductase inhibitors (ARIs) is currently very important…we have investigated the inhibitory effects of extracts and their fractions from two Cannabis sativa L. chemotypes with high content of cannabidiol (CBD)/cannabidiolic acid (CBDa) and cannabigerol (CBG)/cannabigerolic acid (CBGa), respectively, on human recombinant and pig kidney aldose reductase activity in vitro. A molecular docking study was performed to evaluate the interaction of these cannabinoids with the active site of ALR2 compared to known ARIs. The extracts showed significant dose-dependent aldose reductase inhibitory activity (>70%) and higher than fractions. The inhibitory activity of the fractions was greater for acidic cannabinoid-rich fractions [CBDa, CBGa].” Source Cited
  • Metabolic Disorders like Diabetes and Dyslipidemia: “Our work broadens the activity spectrum of CBDa, CBGa, and CBG by providing evidence that these pCBs act as dual PPARα/γ agonists with the ability to modulate the lipid metabolism.” “Dual PPARα/γ agonists have emerged as an attractive alternative to selective PPAR agonists to treat metabolic disorders. We identified some pCBs as dual PPARα/γ agonists, potentially useful for the treatment of dyslipidemia and type 2 diabetes mellitus.” Source Cited
  • MRSA (Staphylococcus aureus): “One phytocannabinoid, cannabichromenic acid (CBCa), demonstrated faster and more potent bactericidal activity than vancomycin, the currently recommended antibiotic for the treatment of MRSA infections. Such bactericidal activity was sustained against low-and high-dose inoculums as well as exponential- and stationary-phase MRSA cells. Further, mammalian cell viability was maintained in the presence of CBCa. Finally, microscopic evaluation suggests that CBCa may function through the degradation of the bacterial lipid membrane and alteration of the bacterial nucleoid. The results of the current study provide encouraging evidence that cannabinoids may serve as a previously unrecognized resource for the generation of novel antibiotics active against MRSA.” Source Cited

Works Cited


Peer-reviewed articles for FULL SPECTRUM SYNERGY Playshops and Pamphlets:

Andre, Christelle M., et al. “Cannabis Sativa: The Plant of the Thousand and One Molecules.” Frontiers in Plant Science, vol. 7, 2016,                 doi:10.3389/fpls.2016.00019.

Izzo, Angelo A, et al. “Non-Psychotropic Plant Cannabinoids: New Therapeutic Opportunities from an Ancient Herb.” Trends in                           Pharmacological Sciences, vol. 30, no. 12, 2009, p. 609., doi:10.1016/

Maccallum, Caroline A., and Ethan B. Russo. “Practical Considerations in Medical Cannabis Administration and Dosing.” European                   Journal of Internal Medicine, vol. 49, 2018, pp. 12–19., doi:10.1016/j.ejim.2018.01.004.

McPartland, J. M., & Russo, E. B. (2001). Cannabis and cannabis extracts: Greater than the sum of their parts? Journal of Cannabis                   Therapeutics, 1(3–4), 103–132. 1300/J175v01n03_08.

Romano, Luigi., Hazekamp, Arno. “Cannabis oil: chemical evaluation of an upcoming cannabis-based medicine.” IACM Journal,                          vol. 1(1), 2013, pp. 1-11.

Russo, Ethan & Marcu, Jahan. (2017). Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Advances in                                Pharmacology. 10.1016/bs.apha.2017.03.004.

Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid terpenoid entourage effects. British Journal of                    Pharmacology, 163(7), 1344–1364. http://

Russo, E. B. (2013). Cannabis strains: Do cannabis strains differ? Retrieved January 18, 2017, from http://www.cannabis-                            ¼faq&red¼faqlist&id¼278&lng¼en.

Russo, E. B. (2019). The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No “Strain,” No Gain.                                 Frontiers in Plant Science”. Vol 9, Article 1969. Doi: 10.3389/fpls.2018.01969                                         10.3389/fpls.2018.01969/full

Russo, E. B., & Guy, G. W. (2006). A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol                                  and cannabidiol. Medical Hypotheses, 66(2), 234–246.

Sinclair, Justin. An introduction to cannabis and the endocannabinoid system. Australian Journal of Herbal Medicine, Vol. 28,                               No. 4, 2016: 107-125.

Whittle, Brian A., et al. “Prospects for New Cannabis-Based Prescription Medicines.” Journal of Cannabis Therapeutics, vol. 1,                                no. 3-4, 2001, pp. 183–205., doi:10.1300/j175v01n03_12.

Zgair, A., Wong, J.C., Lee, J.B., Mistry, J., Sivak, O., Wasan, K.M., Hennig, I.M., Barrett, D.A., Constantinescu, C.S., Fischer, P.M.,                        Gershkovich, P. (2016). Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered                              cannabis and cannabis-based medicines. American journal of translational research, 8(8), 3448-59.                                                               

Zgair, A., et al. (2017). Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system              and prominent immunomodulation. Scientific Reports, 7, Article 14542.